Production of a PEGylated Fab′ of the anti-LINGO-1 Li33 antibody and assessment of its biochemical and functional properties in vitro and in a rat model of remyelination

Bioconjugate Chemistry

Volumn 22, Issue 2, 2011, Pages 200-210

  Pepinsky, R Blake ^a   Walus, Lee ^a   Shao, Zhaohui ^a   Ji, Benxiu ^a   Gu, Sheng ^a   Sun, Yaping ^a   Wen, Dingyi ^a   Lee, Xinhua ^a   Wang, Qin ^a   Garber, Ellen ^a   Mi, Sha ^a  

^a BIOGEN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; CYSTEINE; FAB PROTEIN; LINGO 1 LI33 ANTIBODY; METHOXY POLY(ETHYLENE GLYCOL) MALEIMIDE; POLYMER; PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; BIOENGINEERING; CHEMICAL ANALYSIS; CHEMICAL REACTION; CHO CELL; CONTROLLED STUDY; DEMYELINATION; HEAVY CHAIN; IN VITRO STUDY; IN VIVO STUDY; MYELINATION; NONHUMAN; PROCESS OPTIMIZATION; RAT; REMYELINIZATION;

RATTUS;

EID: 79951694393     PISSN: 10431802     EISSN: 15204812     Source Type: Journal    
DOI: 10.1021/bc1002746     Document Type: Article

References (31)

1. Aires da Silva, F., Corte-Real, S., and Goncalves, J. (2008) Recombinant antibodies as therapeutic agents: pathways for modeling new biodrugs BioDrugs 22, 301-314
2. Salfeld, J. G. (2007) Isotype selection in antibody engineering Nat. Biotechnol. 25, 1369-1372 (Pubitemid 350233124)
3. Labrijn, A. F., Aalberse, R. C., and Schuurman, J. (2008) When binding is enough: nonactivating antibody formats Curr. Opin. Immunol. 20, 479-485
4. Chapman, A. P. (2002) PEGylated antibodies and antibody fragments for improved therapy: a review Adv. Drug Delivery Rev. 54, 531-545 (Pubitemid 34615547)
5. Francis, G. E., Fisher, D., Delgado, C., Malik, F., Gardiner, A., and Neale, D. (1998) PEGylation of cytokines and other therapeutic proteins and peptides: the importance of biological optimization of coupling techniques Int. J. Hematol. 68, 1-18
6. Pepinsky, R. B., Shapiro, R. I., Wang, S, Chakraborty, A., Gill, A., Lepage, D. J., Wen, D., Rayhorn, P., Horan, G. S., Taylor, F. R., Garber, E. A., Galdes, A., and Engber, T. M. (2002) Long-acting forms of Sonic hedgehog with improved pharmacokinetic and pharmacodynamic properties are efficacious in a nerve injury model J. Pharm. Sci. 91, 371-387
7. Baker, D. P., Lin, E. Y., Lin, K., Pellegrini, M., Petter, R. C., Chen, L. L., Arduini, R. M., Brickelmaier, M., Wen, D., Hess, D. M., Chen, L., Grant, D., Whitty, A., Gill, A., Lindner, D. J., and Pepinsky, R. B. (2006) N-terminally PEGylated human interferon-beta-1a with improved pharmacokinetic properties and in vivo efficacy in a melanoma angiogenesis model Bioconjugate Chem. 17, 179-188
8. Kontermann, R. E. (2009) Strategies to extend plasma half-lives of recombinant antibodies BioDrugs 23, 93-109
9. Leong, S. R., DeForge, L., Presta, L., Gonzalez, T., Fan, A., Reichert, M., Chuntharapai, A., Kim, K. J., Tumas, D. B., Lee, W. P., Gribling, P., Snedecor, B., Chen, H., Hsei, V., Schoenhoff, M., Hale, V., Deveney, J., Koumenis, I., Shahrokh, Z., McKay, P., Galan, W., Wagner, B., Narindray, D., Hébert, C., and Zapata, G. (2001) Adapting pharmacokinetic properties of a humanized anti-interleukin-8 antibody for therapeutic applications using site-specific pegylation Cytokine 16, 106-119
10. Knight, D. M., Jordan, R. E., Kruszynski, M., Tam, S. H., Giles-Komar, J., Treacy, G., and Heavner, G.A. (2004) Pharmacodynamic enhancement of the anti-platelet antibody fab abciximab by site-specific pegylation Platelets 15, 409-418
11. Humphreys, D. P., Heywood, S. P., Henry, A, Ait-Lhadj, L., Antoniw, P., Palframan, R., Greenslade, K. J., Carrington, B., Reeks, D. G., Bowering, L. C., West, S., and Brand, H. A. (2007) Alternative antibody Fab' fragment PEGylation strategies: combination of strong reducing agents, disruption of the interchain disulphide bond and disulphide engineering Protein Eng. Des. Sel. 20, 227-234
12. Veronese, F. M. and Mero, A. (2008) The impact of PEGylation on biological therapies BioDrugs 22, 315-329
13. Goel, N. and Stephens, S. (2010) Certolizumab pegol MAbs 2, 137-147
14. Mi, S., Miller, R. H., Lee, X., Scott, M. L., Shulag-Morskaya, S., Shao, Z., Chang, J., Thill, G., Levesque, M., Zhang, M., Hession, C., Sah, D., Trapp, B., He, Z., Jung, V., McCoy, J. M., and Pepinsky, R. B. (2005) LINGO-1 negatively regulates myelination by oligodendrocytes Nat. Neurosci. 8, 745-751
15. Mi, S., Hu, B., Hahm, K., Luo, Y., Kam Hui, E. S., Yuan, Q., Wong, W. M., Wang, L., Su, H., Chu, T. H., Guo, J., Zhang, W., So, K. F., Pepinsky, B., Shao, Z., Graff, C., Garber, E., Jung, V., Wu, E. X., and Wu, W. (2007) LINGO-1 antagonist promotes spinal cord remyelination and axonal integrity in MOG-induced experimental autoimmune encephalomyelitis Nat. Med. 13, 1228-1233
16. Mi, S., Miller, R. H., Tang, W., Lee, X., Hu, B., Wu, W., Zhang, Y., Shields, C. B., Zhang, Y., Miklasz, S., Shea, D., Mason, J., Franklin, R. J., Ji, B., Shao, Z., Chédotal, A., Bernard, F., Roulois, A., Xu, J., Jung, V., and Pepinsky, B. (2009) Promotion of central nervous system remyelination by induced differentiation of oligodendrocyte precursor cells Ann. Neurol. 65, 304-315
17. Pepinsky, R. B., Silvian, L., Berkowitz, S. A., Farrington, G., Lugovskoy, A., Walus, L., Eldredge, J., Capili, A., Mi, S., Graff, C., and Garber, E. (2010) Improving the solubility of anti-LINGO-1 monoclonal antibody Li33 by isotype switching and targeted mutagenesis Protein Sci. 19, 954-966
18. Parren, P. W., Warmerdam, P. A., Boeije, L. C., Arts, J., Westerdaal, N. A., Vlug, A., Capel, P. J., Aarden, L. A., and van de Winkel, J. G. (1992) On the interaction of IgG subclasses with the low affinity Fc gamma RIIa (CD32) on human monocytes, neutrophils, and platelets. Analysis of a functional polymorphism to human IgG2 J. Clin. Invest. 90, 1537-1546
19. Allen, M. J., Guo, A., Martinez, T., Han, M., Flynn, G. C., Wypych, J., Liu, Y. D., Shen, W. D., Dillon, T. M., Vezina, C., and Balland, A. (2009) Interchain disulfide bonding in human IgG2 antibodies probed by site-directed mutagenesis Biochemistry 48, 3755-3766
20. Dillon, T. M., Ricci, M. S., Vezina, C., Flynn, G. C., Liu, Y. D., Rehder, D. S., Plant, M., Henkle, B., Li, Y., Deechongkit, S., Varnum, B., Wypych, J., Balland, A., and Bondarenko, P. V. (2008) Structural and functional characterization of disulfide isoforms of the human IgG2 subclass J. Biol. Chem. 283, 16206-16215
21. Zhang, B., Harder, A. G., Connelly, H. M., Maheu, L. L., and Cockrill, S. L. (2010) Determination of Fab-hinge disulfide connectivity in structural isoforms of a recombinant human immunoglobulin G2 antibody Anal. Chem. 82, 1090-1099
22. Gu, S., Wen, D., Weinreb, P. H., Sun, Y., Zhang, L., Foley, S. F., Kshirsagar, R., Evans, D., Mi, S., Meier, W., and Pepinsky, R.B. (2010) Characterization of trisulfide modification in antibodies Anal. Biochem. 400, 89-98
23. Wilcock, D. M., Alamed, J., Gottschall, P. E., Grimm, J., Rosenthal, A., Pons, J., Ronan, V., Symmonds, K., Gordon, M. N., and Morgan, D. (2006) Deglycosylated anti-amyloid-beta antibodies eliminate cognitive deficits and reduce parenchymal amyloid with minimal vascular consequences in aged amyloid precursor protein transgenic mice J. Neurosci. 26, 5340-5346
24. Carty, N. C., Wilcock, D. M., Rosenthal, A., Grimm, J., Pons, J., Ronan, V., Gottschall, P. E., Gordon, M. N., and Morgan, D. (2006) Intracranial administration of deglycosylated C-terminal-specific anti-Abeta antibody efficiently clears amyloid plaques without activating microglia in amyloid-depositing transgenic mice J. Neuroinflammation 3, 1-11
25. Takata, K., Hirata-Fukae, C., Becker, A. G., Chishiro, S., Gray, A. J., Nishitomi, K., Franz, A. H., Sakaguchi, G., Kato, A., Mattson, M. P., Laferla, F. M., Aisen, P. S., Kitamura, Y., and Matsuoka, Y. (2007) Deglycosylated anti-amyloid beta antibodies reduce microglial phagocytosis and cytokine production while retaining the capacity to induce amyloid beta sequestration Eur. J. Neurosci. 26, 2458-2468
26. Saeland, E., Vidarsson, G., Leusen, J. H., Van Garderen, E., Nahm, M. H., Vile-Weekhout, H., Walraven, V., Stemerding, A. M, Verbeek, J. S., Rijkers, G. T., Kuis, W., Sanders, E. A., and Van De Winkel, J. G. (2003) Central role of complement in passive protection by human IgG1 and IgG2 anti-pneumococcal antibodies in mice J. Immunol. 170, 6158-6164
27. Yoo, E. M., Wims, L. A., Chan, L. A., and Morrison, S. L. (2003) Human IgG2 can form covalent dimers J. Immunol. 170, 3134-3138
28. Zhang, Y. and Pardridge, W. M. (2001) Mediated efflux of IgG molecules from brain to blood across the blood-brain barrier J. Neuroimmunol. 114, 168-172
29. Taylor, F. R., Prentice, H. L., Garber, E. A., Fajardo, H. A., Vasilyeva, E., and Pepinsky, R. B. (2006) Suppression of sodium dodecyl sulfate-polyacrylamide gel electrophoresis sample preparation artifacts for analysis of IgG4 half-antibody Anal. Biochem. 353, 204-208
30. Aalberse, R. C. and Schuurman, J. (2002) IgG4 breaking the rules Immunology 105, 9-19
31. Garber, E. and Demarest, S. J. (2007) A broad range of Fab stabilities within a host of therapeutic IgGs Biochem. Biophys. Res. Commun. 355, 751-757